-
- Shunsuke Ogata, Yoshito Ishii, Keiichiro Asano, Erena Kobayashi, Shun Kubota, Keita Takahashi, Yosuke Miyaji, Yuichi Higashiyama, Hideto Joki, Hiroshi Doi, Michiaki Koga, Hideyuki Takeuchi, and Fumiaki Tanaka.
- Department of Neurology and Stroke Medicine, Yokohama City University Graduate School of Medicine, Japan.
- Intern. Med. 2022 Jun 1; 61 (11): 1757-1760.
AbstractGuillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..